securities fraud

Class action lawsuit filed against $ALIT over alleged false statements on growth and cost-cutting. Stock fell 18.3% in August 2025, 38.2% in February 2026 following earnings misses.

Class action filed against Picard Medical ($PMI) for alleged securities fraud involving false promotions, insider share dumping, and omitted risk disclosures. Lead plaintiff deadline April 3, 2026.

Class action lawsuit filed against $UQRR alleging materially false statements about FDA approval and BLA timeline delays. Investors urged to join by April 13, 2026 deadline.

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy development and clinical trials, covering investors from February 2022 through January 2026.

Class action lawsuit filed against $PYPL alleging executives made false statements about revenue projections and 2027 targets under CEO James Chriss.

Class action filed against PomDoctor ($POM) alleging stock fraud through false statements, social media misinformation, and coordinated insider share dumping.

Law firm files class action against Kyndryl for alleged securities fraud, false financial statements, and internal control failures affecting investors from August 2024 through February 2026.

Masonite faces class action alleging it failed to disclose Owens Corning acquisition offers while repurchasing stock at depressed prices from June 2023 to February 2024.

Paysafe faces securities fraud lawsuit alleging undisclosed high-risk merchant exposure and understated credit reserves during nine-month period through November 2025.

Portnoy Law Firm files class action against $AQST for allegedly misleading investors about Anaphylm FDA prospects. Stock plunged 37% after deficiency disclosure.

Portnoy Law Firm launches class action lawsuit against Alight, Inc. for allegedly making false revenue statements. Stock plummeted 56% cumulatively across two separate crashes in 2025-2026.

Portnoy Law Firm files class action against Camping World Holdings ($CWH) for allegedly making false statements about inventory management and consumer demand between April 2025 and February 2026.

Portnoy Law Firm launches class action against Apollo Global Management alleging undisclosed Epstein communications. Stock declined 5-6% following February 2026 media revelations.

Driven Brands faces securities lawsuit over material accounting errors spanning 2023-2025. Stock fell 40% after February disclosure; investors have until May 8, 2026 to claim lead plaintiff status.

Trip.com faces class action lawsuit alleging securities fraud over undisclosed antitrust risks. Stock fell 19% after China's January 2026 investigation.

$DRVN stock crashed 40% after material accounting restatements spanning 2023-2025. Class action deadline for investors with $100K+ losses set for May 8, 2026.

Soleno Therapeutics ($SLNO) faces class action lawsuit alleging executives failed to disclose material safety concerns with its lead drug DCCR, with lead plaintiff deadline set for May 5, 2026.

Navan faces securities lawsuit over allegedly undisclosed $95 million Q3 sales-marketing expense surge; investors with $100K+ losses have until April 2026 to file.

FDA rejects Corcept's lead drug candidate, triggering 50% stock plunge and securities class action lawsuit. Lead plaintiff deadline set for April 21, 2026.

Enphase Energy shareholders must file lead plaintiff applications by April 20, 2026 in a class action alleging disclosure failures regarding inventory management and tax credit impacts.